Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tizanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 12/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 10/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 10/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.97 |
| ▸ | LMNA | P02545 | 5/20 | 0.97 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.97 |
| ▸ | HRH2 | P25021 | 2/20 | 0.97 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.59 |
| ▸ | BLM | P54132 | 3/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tizanidine SCHEMBL41199 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2469048 | 0.99 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL20769844 | 0.99 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL60334 | 0.99 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL23498010 | 0.97 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2471445 | 0.92 | ADRA2A (0.86) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL4725711 | 0.92 | ADRA2A (0.86) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL28207600 | 0.92 | ADRA2A (0.86) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2469648 | 0.91 | ADRA2A (0.84) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL28345161 | 0.91 | ADRA2A (0.84) | ADRA2AADRA2BADRA2CADRA1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414580-A1 | TIZANIDINE LIQUID PREPARATION AND USE THEREOF | SICHUAN CREDIT PHARMACEUTICAL CO., LTD (CN) | 2023-12-28 | — | — | US | claimed |
| US-12042484-B2 | Tizanidine liquid preparation and use thereof | FIDELITY BIOPHARMA CO. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240148703-A1 | TIZANIDINE LIQUID PREPARATION AND USE THEREOF | SICHUAN CREDIT PHARMACEUTICAL CO., LTD (CN) | 2024-05-09 | — | — | US | disclosed |
| US-20230414580-A1 | TIZANIDINE LIQUID PREPARATION AND USE THEREOF | SICHUAN CREDIT PHARMACEUTICAL CO., LTD (CN) | 2023-12-28 | — | — | US | disclosed |
| WO-2005112911-A2 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042484-B2 | Tizanidine liquid preparation and use thereof | TNNC1, TNNI3, TTN | ADRA2A 503/4885ADRA2B 556/4885ADRA2C 672/4885 |
| US-20240148703-A1 | TIZANIDINE LIQUID PREPARATION AND USE THEREOF | TNNC1, TNNI3, TTN | ADRA2A 503/4885ADRA2B 556/4885ADRA2C 672/4885 |
| US-20230414580-A1 | TIZANIDINE LIQUID PREPARATION AND USE THEREOF | TNNC1, TNNI3, TTN | ADRA2A 503/4885ADRA2B 556/4885ADRA2C 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.